Literature DB >> 18665801

Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Smita Kulkarni1, Srikanth Tripathy, Raman Gangakhedkar, Sushama Jadhav, Kalpana Agnihotri, Suvarna Sane, Robert Bollinger, Ramesh Paranjape.   

Abstract

The longitudinal heterologous neutralization response against two HIV-1 subtype C isolates was studied in 33 ART-naive individuals recently infected with HIV-1 subtype C from India. Seven of 33 (21%) seroconverters demonstrated a consistent response against both isolates (65-100% neutralization), whereas the remaining 26 (79%) were nonresponders. Four of the seven responders demonstrated a neutralization response (>75% neutralization) within 2-3 months of infection and in the remaining three, the response was demonstrated between 22 and 38 months after infection. In the past, HIV vaccines targeted the V3 region for the development of neutralizing antibodies. However, recent studies have shown that anti-V3 antibodies are generated after HIV-1 infection, but are not effective in neutralizing virus. In this study, the V3 sequences of HIV-1 from seven responders were analyzed and compared with those from nonresponders. The V3 region sequences from early and late responders did show certain mutations that were not found in the nonresponders; however none of these mutations could explain the neutralization responses. This suggested that HIV-1 envelope regions other than the V3 domain may be involved in generating a neutralization response. This is the first report that describes the pattern of emergence and persistence of the heterologous neutralization response in recently HIV-1 subtype C-infected individuals from India and studies its association with sequence variation in the V3 region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665801      PMCID: PMC2928029          DOI: 10.1089/aid.2007.0296

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Authors:  P N Nyambi; H A Mbah; S Burda; C Williams; M K Gorny; A Nádas; S Zolla-Pazner
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences.

Authors:  R Shankarappa; R Chatterjee; G H Learn; D Neogi; M Ding; P Roy; A Ghosh; L Kingsley; L Harrison; J I Mullins; P Gupta
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Authors:  Renata Bures; Lynn Morris; Carolyn Williamson; Gita Ramjee; Mark Deers; Susan A Fiscus; Salim Abdool-Karim; David C Montefiori
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Authors:  David C Montefiori; Marcus Altfeld; Paul K Lee; Miroslawa Bilska; Jintao Zhou; Mary N Johnston; Feng Gao; Bruce D Walker; Eric S Rosenberg
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

10.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  4 in total

1.  Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected].

Authors:  Alok Kumar Choudhary; Raiees Andrabi; Somi Sankaran Prakash; Rajesh Kumar; Shubhasree Dutta Choudhury; Naveet Wig; Ashutosh Biswas; Anjali Hazarika; Kalpana Luthra
Journal:  J Microbiol       Date:  2012-02-27       Impact factor: 3.422

2.  Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1.

Authors:  Teena Mohan; D Mitra; D N Rao
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

3.  Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.

Authors:  Jianming Tang; Emmanuel Cormier; Jill Gilmour; Matthew A Price; Heather A Prentice; Wei Song; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

4.  Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships.

Authors:  Jianming Tang; Rakhi Malhotra; Wei Song; Ilene Brill; Liangyuan Hu; Paul K Farmer; Joseph Mulenga; Susan Allen; Eric Hunter; Richard A Kaslow
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.